Assessment of Hazard Risk Associated with the Intravenous Use of Viral Vectors in Rodents
Abstract:Viral vectors are emerging as potent basic research tools and gene therapy vehicles in many laboratory animal models. However, little information is available on the potential shedding of these vectors and the consequent exposure risk to investigators and animal care staff from animals over time. This study provides empirical information to Institutional Biosafety Committees and animal care programs, to enhance their ability to perform risk management of laboratory animals treated with viral vectors. Control experiments evaluated the limit of detection of third-generation lentivirus, recombinant adeno-associated virus, and E1-deleted adenovirus tested directly from stocks and after application onto cage plastic or bedding. After inoculation of ICR or NOD-SCID mice, we quantified the recovery of viral vector genomes directly from blood, urine, and fecal samples and assessed the persistence of infectious vector at the site of injection and from soiled bedding at different time points after inoculation. No differences were seen between ICR and NOD-SCID mice. We saw no evidence of vector amplification after in vivo inoculation. The most environmentally persistent vector was recombinant adeno-associated virus, which has no known pathogenicity in humans. In light of these data, we conclude that commonly used replication-deficient viral vectors pose minimal exposure risk by 72 h after inoculation. Prudent precautions at Animal Biosafety Level 2 are warranted during initial administration, but Level 1 safety measures may be sufficient after cage changing and biosafety evaluation.
Document Type: Research Article
Affiliations: 1: Animal Resources Department, The Salk Institute for Biological Studies, La Jolla, California, USA. firstname.lastname@example.org 2: GT3 Core Facility, The Salk Institute for Biological Studies, La Jolla, California, USA 3: Animal Resources Department, The Salk Institute for Biological Studies, La Jolla, California, USA
Publication date: October 1, 2012
Comparative Medicine (CM), an international journal of comparative and experimental medicine, is the leading English-language publication in the field and is ranked by the Science Citation Index in the upper third of all scientific journals. The mission of CM is to disseminate high-quality, peer-reviewed information that expands biomedical knowledge and promotes human and animal health through the study of laboratory animal disease, animal models of disease, and basic biologic mechanisms related to disease in people and animals.
Attention Members: To access the full text of the articles, be sure you are logged in to the AALAS website.
Attention: please note, due to a temporary technical problem, reference linking within the content is not available at this time
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Membership Information
- Information for Advertisers
- For issues prior to 1998
- Institutional Subscription Activation
- Ingenta Connect is not responsible for the content or availability of external websites